Low-dose temozolomide modulation of peripheral blood regulatory T cells before dendritic cell-based vaccination in metastatic melanoma: Phase I/II study

被引：0
|
作者：
Ridolfi, L.
Fiammenghi, L.
Petrini, M.
Granato, A.
Ancarani, V.
Pancisi, E.
Guidoboni, M.
Riccobon, A.
Ascierto, P. A.
Ridolfi, R.
机构：
[1] Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
[2] Ist Nazl Tumori Pascale, Naples, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps311
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS311
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Autologous T cell stimulatory capacity and cell yields of peripheral blood mononuclear cells for dendritic cell-based immunotherapy differ between cryopreservation protocols
    Buhl, T.
    Legler, T. J.
    Rosenberger, A.
    Schardt, A.
    Schoen, M. P.
    Haenssle, H. A.
    EXPERIMENTAL DERMATOLOGY, 2012, 21 (03) : e32 - e32
  • [32] A phase I/II study of Xcellerated T cells™ after autologous peripheral blood stem cell transplantation in patients with multiple myeloma
    Vij, R
    Vescio, RA
    Borrello, IM
    Martin, TG
    Siegel, D
    Berenson, JR
    Janmohamed, F
    Berenson, RJ
    Frohlich, MW
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (02) : 76 - 76
  • [33] A phase I/II study of Xcellerated T cells™ after autologous peripheral blood stem cell transplantation in patients with multiple myeloma
    Martin, T
    Vij, R
    Vescio, R
    Borrello, I
    Siegel, D
    Bashey, A
    DiPersio, J
    Berenson, J
    Ferrand, C
    Janmohamed, F
    Yuan, V
    Bouchard, L
    Hami, L
    Berenson, RJ
    Bonyhadi, M
    Frohlich, MW
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) : 27 - 28
  • [34] Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma.
    Jameson-Lee, Max
    Ott, Patrick Alexander
    Luke, Jason J.
    Postow, Michael A.
    Poklepovic, Andrew Stewart
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer
    Rahman, Z
    Champlin, R
    Rondon, G
    Frye, D
    Valero, V
    Mehra, R
    Hortobagyi, G
    SEMINARS IN ONCOLOGY, 1997, 24 (05) : 77 - 80
  • [36] Continuous Administration of Daily Low-Dose Temozolomide in Pretreated Patients with Advanced Non-Small Cell Lung Cancer: A Phase II Study
    Kouroussis, Charalambos
    Vamvakas, Lambros
    Vardakis, Nikolaos
    Kotsakis, Athanasios
    Kalykaki, Antonia
    Kalbakis, Kostas
    Saridaki, Zacharenia
    Kentepozidis, Nikolaos
    Giassas, Stelios
    Georgoulias, Vassilis
    ONCOLOGY, 2009, 76 (02) : 112 - 117
  • [37] Phase II study of pembrolizumab in conjunction with lymphodepletion, TIL ACT, and high- or low-dose IL-2 in patients with metastatic melanoma
    Hasanov, Merve
    Kiany, Simin
    Forget, Marie-Andree
    Bassett, Roland L.
    Davies, Michael A.
    Diab, Adi
    Gershenwald, Jeffrey E.
    Glitza, Isabella C.
    Lee, Jeffrey E.
    Lucci, Anthony
    McQuade, Jennifer L.
    Patel, Sapna P.
    Ross, Merrick I.
    Tawbi, Hussein A.
    Wargo, Jennifer
    Wong, Michael K.
    Bernatchez, Chantale
    Hwu, Patrick
    Haymaker, Cara
    Amaria, Rodabe N.
    CANCER RESEARCH, 2024, 84 (06)
  • [38] METASTATIC RENAL-CELL CANCER TREATED WITH LOW-DOSE INTERLEUKIN-2 - A PHASE-II MULTICENTER STUDY
    STOTER, G
    FOSSA, SD
    RUGARLI, C
    SYMANN, M
    JASMIN, C
    ISRAEL, L
    BIJMAN, JT
    PALMER, P
    FRANKS, CR
    PHILIP, T
    CANCER TREATMENT REVIEWS, 1989, 16 : 111 - 113
  • [39] A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma
    Koch, Elias A. T.
    Schaft, Niels
    Kummer, Mirko
    Berking, Carola
    Schuler, Gerold
    Hasumi, Kenichiro
    Doerrie, Jan
    Schuler-Thurner, Beatrice
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [40] Vaccination with allogeneic, partially HLA-matched dendritic cells (DC) in metastatic renal cell cancer (mRCC)- final analysis of a clinical phase I/II study
    Floercken, A.
    Kopp, J.
    Movassaghi, K.
    van Lessen, A.
    Takvorian, A.
    Schoenemann, C.
    Joehrens, K.
    Moebs, M.
    Sawitzki, B.
    Doerken, B.
    Pezzutto, A.
    Westermann, J.
    ONKOLOGIE, 2012, 35 : 63 - 63
12345